PALBOCOMP: Retrospective observational analysis of palbociclib treatment in patients with advanced breast cancer within a compassionate use program in Spain
Luís Manso(Research Institute Hospital 12 de Octubre), Fernando Moreno(Hospital Clínico San Carlos), Elena Aguirre(Hospital Quirón Teknon), Ignacio Delgado(Universitat Autònoma de Barcelona), Michael J. González(Hospital Universitario Dexeus), José Enrique Alés(Hospital Nuestra Señora de Alarcos), César A. Rodríguez(Complejo Hospitalario de Salamanca), Diego Malón(Hospital Universitario de Fuenlabrada), A. Oltra(Hospital Virgen de los Lirios), Begoña Bermejo(Hospital Clínico Universitario de Valencia)
Cited by 0
Related Papers
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
|JNCI Journal of the National Cancer Institute|2019|168
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
|Journal of Clinical Oncology|2012|163